| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699384 | Clinical Oncology | 2013 | 7 Pages |
Abstract
Oral ridaforolimus (40Â mg QDx5/wk) is feasible to combine with standard doses of bevacizumab, although careful patient selection would be needed to mitigate the risk of bowel perforation-related adverse events. Combination therapy produced prolonged stable disease in several heavily pretreated patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Nemunaitis, H.S. Hochster, S. Lustgarten, R. Rhodes, S. Ebbinghaus, C.D. Turner, P.F. Dodion, M.M. Mita,